Xcode can now connect to external AI coding agents, making it possible to prototype working apps with minimal programming experience.

If you’ve been watching the JavaScript landscape for a while, you’ve likely noticed the trend toward simplicity in web application development. An aspect of this trend is leveraging HTML, REST, and ...

People are already turning to AI to answer questions, compare products, and make decisions in seconds. That shift exposes a fundamental problem: the web’s underlying structure was never built for ...

Your favorite latte at the local coffee shop could soon cost $5, $5.10 or $5.25—depending on how you pay. A settlement between Visa, Mastercard and U.S. merchants announced this week could usher in a ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

You’re going to want to sit down for this. Ask Well You’re going to want to sit down for this. Credit...Eric Helgas for The New York Times Supported by By Melinda Wenner Moyer Q: I love browsing ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...

LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) violations of §§10(b) and 20(a) ...